R. Cathomas

Discipline

Economies et finances (2)

Type de document

Articles (7) Recensions (1)

Co-auteur

Date

Source

Mot-clé

maladie (6) Treatment (6) Patients (6) Cancer (6) Patients (6) maladie (6) procès (5) cancer (5) survie (5) Cancer (5) Swiss (5) Survival (5) thérapie (4) oncologie (4) Chemotherapy (4) Therapeutics (4) Oncology (4) Months (4) Chemotherapy (4) toxicité (3) âge (3) Methods (3) Ci (Chinese poetry) (3) Theater (3) Management (3) Human beings (3) Drama (3) Age (3) Acting (3) Methods (3)

Documents écrit par R. Cathomas (7) | parle de R. Cathomas (0)

Interdisciplinary Swiss consensus recommendations on staging and treatment of advanced prostate cancer.
A.J. Templeton et al. (15 août 2023)
Swiss germ-cell cancer consensus recommendations.
J. Beyer et al. (23 août 2021)
Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08).
A. Curioni-Fontecedro et al.
Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer - A Retrospective Analysis of the Swiss Lenvatinib Named Patient Program.
C. Balmelli et al. (2018)
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
N.D. James et al. (19 mars 2016)
SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.
C. Rochlitz et al. (2016)
First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07).
R. von Moos et al. (2012)